11ÔÂ28ÈÕ£¬£¬£¬£¬£¬¹ú¼ÒÒ½ÁÆ°ü¹Ü¾Ö¡¢ÈËÁ¦×ÊÔ´ºÍÉç»á°ü¹Ü²¿ÕýʽÐû²¼ÁË¡¶¹ú¼Ò»ù±¾Ò½ÁÆ°ü¹Ü¡¢¹¤ÉË°ü¹ÜºÍÉúÓý°ü¹ÜҩƷĿ¼(2024Äê)¡·¡£¡£
¡£ÊæËÙ´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ¾­Ì¸ÅÐÊ״α»ÄÉÈë¹ú¼ÒÒ½±£Ä¿Â¼¡£¡£
¡£Ð°æĿ¼½«ÓÚ2025Äê1ÔÂ1ÈÕÕýʽʵÑé¡£¡£
¡£

ÊæËÙ´ï^®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ

       ·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÊô±´ÌØÀàѪ֬µ÷ÀíÒ©£¬£¬£¬£¬£¬Í¨¹ýÒÖÖƼ«µÍÃܶÈÖ¬ÂÑ°×µ¨¹Ì´¼ºÍ¸ÊÓÍÈýõ¥µÄÌìÉú²¢Í¬Ê±Ê¹ÆäÆÊÎö´úлÔö¶à£¬£¬£¬£¬£¬½µµÍѪµÍÃܶÈÖ¬ÂÑ°×µ¨¹Ì´¼ºÍ¸ÊÓÍÈýõ¥£»£»£»»¹Ê¹ÔØÖ¬ÂÑ°×A1ºÍA11ÌìÉúÔöÌí£¬£¬£¬£¬£¬´Ó¶øÔö¸ß¸ßÃܶÈÖ¬ÂÑ°×µ¨¹Ì´¼¡£¡£
¡£ÊæËÙ´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÓÅ»¯µ¨¼îÑνṹ£¬£¬£¬£¬£¬¾ßÓнϺõÄË®ÈÜÐÔ£¬£¬£¬£¬£¬ÏÔÖøÌáÉýÁËÉúÎïʹÓöÈ^[1]£»£»£»Ò»´ÎÒ»Á££¨135mg£©,Ò»ÌìÒ»´Î£¬£¬£¬£¬£¬ÎÞÐèÓë²Íͬ·þ£¬£¬£¬£¬£¬ÌáÉýÓÃÒ©±ãµ±ÐÔ^[2]¡£¡£
¡£¿£¿ÉÖ±½ÓÔÚÌåÄÚÊ©Õ¹×÷Ó㬣¬£¬£¬£¬ÎÞÐè¾­ÓɸÎÔàÊ×¹ý´úл£¬£¬£¬£¬£¬´Ó¶ø¿É½µµÍ¸ÎÔà¼ç¸º^[1]¡£¡£
¡£ËµÃ÷ÊéÖ¸³ö£¬£¬£¬£¬£¬±¾Æ·ÓëËûÍ¡ÀàÒ©ÎïÁªºÏʹÓÃÎÞÐèµ÷½â±¾Æ·»òÊÊÓÃÒ©ÎïµÄ¼ÁÁ¿¡£¡£
¡£

ÏàÖú×ÉѯÈÈÏß:4001833668

¿ÉɨÂë¹ÒºÅÏàÖúÐÅÏ¢

²Î¿¼×ÊÁÏ£º

[1]     Elisavet Moutzouri ,Anastazia Kei,Moses S elisaf ,Haralampos J Milionis.Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.Vascular Health and Risk Management 2010:6 525–539.

[2]   ·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ˵Ã÷Êé.